34 filings
Page 2 of 2
8-K
n4cubzpa hxfdw
21 May 18
Regulation FD Disclosure
4:14pm
8-K
8qt1o6o98268 2b8
9 May 18
Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results
4:11pm
8-K
b8rzk66 9zmet
20 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
8zwzderrv0z9m m7
3 Apr 18
Termination of a Material Definitive Agreement
12:00am
8-K
uysp44thrp
27 Mar 18
Changes in Registrant's Certifying Accountant
12:00am
8-K
p9igz0w4ou82d4jau9jl
15 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
z7f35
15 Feb 18
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
12:00am
8-K
b4g6v j2ub
31 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
1lgdi9l kd1g
28 Nov 17
Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review
12:00am
8-K
yls5e
9 Nov 17
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results
12:00am
8-K
j3v75by
23 Oct 17
Management Presentation January 2017 Liver Meeting of the American Association for the Study of Liver Diseases October 23rd, 2017
12:00am
8-K
gld65xmfu34sqgxvmy
22 Sep 17
Dova Pharmaceuticals Announces New Drug Application Submission to Fda for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist
12:00am
8-K
pol0zq 00
10 Aug 17
Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results
12:00am
8-K
hyghni9bsd
5 Jul 17
Amendments to Articles of Incorporation or Bylaws
12:00am